ECSP088704A - Derivados de tieno-piridina como inhibidores de mek - Google Patents

Derivados de tieno-piridina como inhibidores de mek

Info

Publication number
ECSP088704A
ECSP088704A EC2008008704A ECSP088704A ECSP088704A EC SP088704 A ECSP088704 A EC SP088704A EC 2008008704 A EC2008008704 A EC 2008008704A EC SP088704 A ECSP088704 A EC SP088704A EC SP088704 A ECSP088704 A EC SP088704A
Authority
EC
Ecuador
Prior art keywords
pyridine derivatives
tieno
mek inhibitors
substituted
mapkk
Prior art date
Application number
EC2008008704A
Other languages
English (en)
Inventor
Daniel Christopher Brookings
Jeremy Martin Davis
Barry John Langham
James A Johnson
Martin Clive Hutchings
Sarah Catherine Archibald
Judi Charlotte Neuss
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Publication of ECSP088704A publication Critical patent/ECSP088704A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Una serie de derivados de tieno[2,3-b]piridina que están sustituidos en la posición 2 con un resto anilino sustituido, que son inhibidores selectivos de las enzimas MEK (MAPKK)humanas, son por consiguiente beneficiosos en medicina, por ejemplo en el tratamiento de afecciones inflamatorias, autoinmunes, cardiovasculares, proliferativas (con inclusión de las oncológicas) y nociceptivas
EC2008008704A 2006-01-31 2008-08-28 Derivados de tieno-piridina como inhibidores de mek ECSP088704A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0601962.4A GB0601962D0 (en) 2006-01-31 2006-01-31 Therapeutic agents

Publications (1)

Publication Number Publication Date
ECSP088704A true ECSP088704A (es) 2008-09-29

Family

ID=36100789

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008704A ECSP088704A (es) 2006-01-31 2008-08-28 Derivados de tieno-piridina como inhibidores de mek

Country Status (26)

Country Link
US (3) US8283359B2 (es)
EP (1) EP1981892B1 (es)
JP (1) JP5249787B2 (es)
KR (1) KR101446919B1 (es)
CN (1) CN101379067B (es)
AU (1) AU2007211377B2 (es)
BR (1) BRPI0708016B1 (es)
CA (1) CA2640594C (es)
CY (1) CY1115404T1 (es)
DK (1) DK1981892T3 (es)
EA (1) EA016128B1 (es)
EC (1) ECSP088704A (es)
ES (1) ES2471970T3 (es)
GB (1) GB0601962D0 (es)
HR (1) HRP20140503T1 (es)
IL (1) IL192603A (es)
MY (1) MY146387A (es)
NO (1) NO341064B1 (es)
NZ (1) NZ569638A (es)
PL (1) PL1981892T3 (es)
PT (1) PT1981892E (es)
RS (1) RS53342B (es)
SI (1) SI1981892T1 (es)
UA (1) UA95939C2 (es)
WO (1) WO2007088345A1 (es)
ZA (1) ZA200807447B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0601962D0 (en) 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
GB0616214D0 (en) * 2006-08-15 2006-09-27 Ucb Sa Therapeutic Agents
GB0714384D0 (en) 2007-07-23 2007-09-05 Ucb Pharma Sa theraputic agents
NZ586575A (en) * 2007-12-21 2012-03-30 Genentech Inc Azaindolizines and methods of use
EP2240494B1 (en) 2008-01-21 2016-03-30 UCB Biopharma SPRL Thieno-pyridine derivatives as mek inhibitors
GB0811304D0 (en) 2008-06-19 2008-07-30 Ucb Pharma Sa Therapeutic agents
JP5503930B2 (ja) * 2009-09-18 2014-05-28 住友化学株式会社 ３−アミノ−１−ｔｅｒｔ−ブトキシカルボニルピペリジンの精製方法およびそのクエン酸塩
WO2012018638A2 (en) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures
EP2598661B1 (en) 2010-07-26 2017-09-27 Biomatrica, INC. Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
EP2934572A4 (en) 2012-12-20 2016-11-23 Biomatrica Inc FORMULATIONS AND METHODS FOR STABILIZING PCR REAGENTS
WO2014130932A2 (en) 2013-02-25 2014-08-28 Novartis Ag Novel androgen receptor mutation
EP3008073B1 (en) 2013-06-11 2020-01-01 Latvian Institute Of Organic Synthesis Thieno[2,3-b]pyridines as multidrug resistance modulators
EP3007556B1 (en) 2013-06-13 2020-05-20 Biomatrica, INC. Cell stabilization
JP6661554B2 (ja) 2014-06-10 2020-03-11 バイオマトリカ，インク． 周囲温度における血小板の安定化
CN105384754B (zh) * 2014-09-02 2018-04-20 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
WO2017033113A1 (en) 2015-08-21 2017-03-02 Acerta Pharma B.V. Therapeutic combinations of a mek inhibitor and a btk inhibitor
JP6827048B2 (ja) 2015-12-08 2021-02-10 バイオマトリカ，インク． 赤血球沈降速度の低下
ES3030506T3 (en) 2017-05-19 2025-06-30 Nflection Therapeutics Inc Pyrrolopyridine-aniline compounds for treatment of dermal disorders
EP3624795B1 (en) * 2017-05-19 2022-04-20 NFlection Therapeutics, Inc. Fused heteroaromatic-aniline compounds for treatment of dermal disorders
CN109836434B (zh) * 2017-11-27 2020-09-25 上海宇耀生物科技有限公司 噻吩并环类化合物及其合成方法和应用
CA3120337A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Naphthyridinone-aniline compounds for treatment of dermal disorders
MA55141A (fr) 2018-11-20 2021-09-29 Nflection Therapeutics Inc Composés cyanoaryl-aniline pour le traitement d'affections de la peau
CA3120351A1 (en) * 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers
JP7546297B2 (ja) * 2018-11-20 2024-09-06 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置のためのチエニル－アニリン化合物
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
CA3159348A1 (en) 2019-11-08 2021-05-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
CN111138449B (zh) * 2020-01-15 2022-11-29 四川大学华西医院 双靶向erk1和erk5抑制剂的制备及其抗肿瘤应用
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US12280055B2 (en) 2021-05-27 2025-04-22 Mirati Therapeutics, Inc. Combination therapies
EP4436570A4 (en) 2021-11-23 2025-10-22 Nflection Therapeutics Inc FORMULATIONS OF PYRROLOPYRIDINE-ANILINE COMPOUNDS
GB202205203D0 (en) 2022-04-08 2022-05-25 UCB Biopharma SRL Combination with inhibitor
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ501277A (en) 1997-07-01 2002-12-20 Warner Lambert Co -2(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
WO2000041505A2 (en) 1999-01-13 2000-07-20 Warner-Lambert Company Anthranilic acid derivatives
HRP20010524A2 (en) 1999-01-13 2002-08-31 Warner Lambert Co Benzoheterocycles and their use as mek inhibitors
CA2416685C (en) 2000-07-19 2008-10-07 Warner-Lambert Company Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
DE60330227D1 (de) 2002-03-13 2010-01-07 Array Biopharma Inc N3-alkylierte benzimidazol-derivate als mek-hemmer
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
RU2300528C2 (ru) 2002-03-13 2007-06-10 Эррэй Биофарма, Инк. N3-алкилированные бензимидазольные производные в качестве ингибиторов мек
US20030225273A1 (en) * 2002-03-21 2003-12-04 Michaelides Michael R. Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
GB0214268D0 (en) * 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
CL2003002287A1 (es) * 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
BR0317183A (pt) * 2002-12-12 2005-11-01 Pharmacia Corp Método de usar compostos de aminocianopiridina como inibidores de proteìna quinase-2 ativada por proteìna quinase ativada por mitógeno
EP1641804A1 (en) 2003-06-20 2006-04-05 Celltech R & D Limited Thienopyridone derivatives as kinase inhibitors
WO2004113348A1 (en) * 2003-06-20 2004-12-29 Celltech R & D Limited Thienopyridone derivatives as kinase inhibitors
US20050049276A1 (en) 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
EP1651214B1 (en) 2003-07-24 2009-09-16 Warner-Lambert Company LLC Benzimidazole derivatives as mek inhibitors
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US20070275962A1 (en) * 2003-09-10 2007-11-29 Gpc Biotech Ag Heterobicyclic Compounds as Pharmaceutically Active Agents
CN1905873A (zh) 2003-11-19 2007-01-31 阵列生物制药公司 Mek的杂环抑制剂及其使用方法
US7217723B2 (en) 2004-02-02 2007-05-15 Eisai Co., Ltd. Heterocyclic compound having oxime group
AU2006284751A1 (en) 2005-09-01 2007-03-08 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
DE602006021205D1 (de) 2005-10-07 2011-05-19 Exelixis Inc Azetidine als mek-inhibitoren bei der behandlung proliferativer erkrankungen
GB0601962D0 (en) 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
TW200808769A (en) 2006-04-18 2008-02-16 Astrazeneca Ab Therapeutic compounds
GB0616214D0 (en) 2006-08-15 2006-09-27 Ucb Sa Therapeutic Agents
JP2010500994A (ja) 2006-08-16 2010-01-14 エグゼリクシス， インコーポレイテッド Ｐｉ３ｋおよびｍｅｋモジュレーターを使用する方法
JP5311673B2 (ja) 2006-12-14 2013-10-09 エグゼリクシス， インコーポレイテッド Ｍｅｋ阻害剤の使用方法
GB0714384D0 (en) 2007-07-23 2007-09-05 Ucb Pharma Sa theraputic agents
EP2240494B1 (en) 2008-01-21 2016-03-30 UCB Biopharma SPRL Thieno-pyridine derivatives as mek inhibitors
GB0811304D0 (en) 2008-06-19 2008-07-30 Ucb Pharma Sa Therapeutic agents

Also Published As

Publication number Publication date
HK1125924A1 (en) 2009-08-21
PT1981892E (pt) 2014-06-23
JP2009525317A (ja) 2009-07-09
BRPI0708016A2 (pt) 2011-05-17
US8604051B2 (en) 2013-12-10
EA200801684A1 (ru) 2009-04-28
GB0601962D0 (en) 2006-03-15
RS53342B (sr) 2014-10-31
NZ569638A (en) 2010-08-27
PL1981892T3 (pl) 2014-08-29
CA2640594A1 (en) 2007-08-09
SI1981892T1 (sl) 2014-07-31
NO341064B1 (no) 2017-08-14
DK1981892T3 (da) 2014-06-23
CA2640594C (en) 2014-12-23
CN101379067B (zh) 2011-03-23
US20130150573A1 (en) 2013-06-13
HRP20140503T1 (hr) 2014-07-04
KR101446919B1 (ko) 2014-10-07
EP1981892B1 (en) 2014-03-12
US8394822B2 (en) 2013-03-12
US20120329774A1 (en) 2012-12-27
US8283359B2 (en) 2012-10-09
WO2007088345A1 (en) 2007-08-09
JP5249787B2 (ja) 2013-07-31
NO20083739L (no) 2008-08-29
MY146387A (en) 2012-08-15
CY1115404T1 (el) 2017-01-04
IL192603A (en) 2013-12-31
CN101379067A (zh) 2009-03-04
ZA200807447B (en) 2009-11-25
UA95939C2 (en) 2011-09-26
IL192603A0 (en) 2009-02-11
AU2007211377B2 (en) 2012-03-01
AU2007211377A1 (en) 2007-08-09
ES2471970T3 (es) 2014-06-27
US20090149437A1 (en) 2009-06-11
EP1981892A1 (en) 2008-10-22
EA016128B1 (ru) 2012-02-28
BRPI0708016B1 (pt) 2021-07-06
KR20080095870A (ko) 2008-10-29

Similar Documents

Publication Publication Date Title
ECSP088704A (es) Derivados de tieno-piridina como inhibidores de mek
NO20060279L (no) Thienopyridonderivater som kinaseinhibitorer
WO2008020206A3 (en) Fused thiophene derivatives as mek inhibitors
MX356086B (es) Produccion de acidos grasos y derivados de los mismos.
CR20110261A (es) COMPUESTOS PIRAZOLO[1,5-a]PIRIMIDINA SUSTITUIDA COMO IHNIBIDORES DE TRK CINASA
ECSP066927A (es) Sintesis regioespecífica de los derivados de 42 - ester de rapamicina
CY1114419T1 (el) Παραγωγα συντηγμενου θειαζολιου ως αναστολεις κινασης
CY1120304T1 (el) Ενωσεις microrna και μεθοδοι για τη διαμορφωση της mir-21 δραστικοτητας
MX2009009371A (es) Produccion mejorada de derivados de acidos grasos.
AR081515A1 (es) Agente de sustentacion de un material vitroceramico
DK2021577T3 (da) Konfigurerbart borehulszoneisolationssystem og tilhørende fremgangsmåder
SG196782A1 (en) Compositions and methods for the increased production of isoprene and other products with 6 - phosphogluconolactonase (pgl)
EP2508600A4 (en) MUTANT ENZYM AND ITS APPLICATION
MX2009004883A (es) Piridil sulfoximinas multi-substituidas y su uso como insecticidas.
DK2254996T3 (da) Lipaser med høj specificitet for kortkædede fedtsyrer og anvendelser deraf
SI2046797T1 (sl) Derivati furo B pirol ona in njihova uporaba kot inhibitorji cisteinil proteinaze
SMT201400013B (it) Attivatori di ampk tieno[2,3-B] piridina dione e loro impieghi terapeutici
BR112014001075A2 (pt) sonda, seu uso, método in vitro para associar uma sonda com um alvo e kit
CU24052B1 (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), y método de producción de los mismos
IS8178A (is) Oxazólidinon fúkalyf setin með sýklóprópýlhóp og afleiður þeirra
CO6710901A2 (es) Método de vitrificación de superficie con nitrógeno líquido
BRPI0722074A2 (pt) Problemas de perda de circulação em uma zona de um furo de poço, e dispositivo
BRPI0816676A2 (pt) Estrutura de furo de corrida para fornalha de fusão e método de reparo do mesmo.
MX2014006088A (es) Biomarcadores para canceres que responden a moduladores de la actividad de hec1.
DK1689222T3 (da) Solsikkeolie, solsikkefrø og solsikkeplanter med modificeret fedtsyrefordeling i triacylglycerolmolekylet